FDA pre-submission feedback supports a Class II strategy, leveraging substantial equivalence to a previously cleared device, positioning the Company for potential initial U.S. clearance of its standalone sensing platform in approximately 15 months

THE WOODLANDS, TX, Sept. 30, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion of a pre-submission meeting with the U.S. Food and Drug Administration (FDA) regarding the Company’s recently announced standalone transvascular sensing platform, which is designed to detect and differentiate faint biological signals.

The FDA interaction provided important guidance regarding Autonomix’s proposed regulatory strategy, validation activities and anticipated submission pathway for the Company’s standalone sensing platform. Based on feedback received, the Company believes it has identified a Class II regulatory pathway that would use an already-cleared reference device to support a substantial-equivalence strategy for its standalone sensing platform.

Subject to successful completion of development and validation activities, and FDA review, Autonomix is targeting potential U.S. clearance in approximately 15 months.

“This FDA interaction gives us greater clarity on the work required to pursue an initial U.S. clearance and represents a significant milestone in advancing our proprietary technology toward the U.S. market,” said Brad Hauser, Chief Executive Officer of Autonomix. “We believe a focused pathway for the standalone sensing platform allows us to pursue a nearer-term regulatory objective, while we continue to build toward the larger opportunity for our technology. Our goal is to establish the sensing foundation first, then expand toward biosignal interpretation and, over time, procedural guidance.”

Autonomix believes successful clearance of the standalone sensing platform could establish a regulatory predicate supporting future generations of its technology platform, including planned signal interpretation and procedular guidance capabilities.

“Our vision is a clear progression: sense, interpret and ultimately guide,” continued Mr. Hauser. “The ability to capture extremely faint biosignals at their source is the critical first step. From there, we believe we can build increasingly powerful computational capabilities, including artificial intelligence, designed to help physicians understand what is happening physiologically, where intervention may be appropriate and what changed following treatment. We believe this staged approach is a disciplined path from standalone sensing toward a broader ‘Sense, Treat and Verify’ platform. We look forward to sharing more in the coming months about how we plan to advance these capabilities.”

The Company will continue development and validation activities associated with its standalone sensing platform while advancing signal interpretation and other advanced computational capabilities for future generations of its platform.

About Autonomix Medical, Inc. 

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
 
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
 
Forward Looking Statements 

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include, but are not limited to, expectations regarding the Company’s anticipated regulatory pathway and strategy for its standalone sensing platform, including the potential for Class II clearance based on substantial equivalence, the anticipated timeline for potential U.S. clearance, the potential for a cleared standalone sensing platform to serve as a regulatory predicate for future product generations, the Company’s staged development plans for its platform, including potential signal interpretation and AI-enabled capabilities, the potential effectiveness and clinical benefits of Autonomix’s nerve-targeted treatments for pancreatic cancer pain and other conditions, the versatility and scalability of the Company’s platform technology, the potential for future clinical applications across multiple organ systems, and the strength and scope of the Company’s intellectual property portfolio.

Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 27, 2026, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor and Media Contact 

JTC Team, LLC 
Jenene Thomas
908.824.0775
autonomix@jtcir.com

The customer transaction arrives with the new $5M facility launch, and additional customer agreements already in the pipeline.

Chicago, IL, Sept. 30, 2026 (GLOBE NEWSWIRE) — Frequency Holdings Inc. (OTC: FRQN), a technology-focused holding company building and acquiring assets across cybersecurity, managed intelligence, digital infrastructure, strategic technology and media, today announced that its wholly owned subsidiary, ReachOut Digital Intelligence, has entered a customer transaction through the new Capchase Pay $5M financing facility announced yesterday. The customer agreement represents nearly $153,000 in contract value.

Frequency Holdings Activates New $5 Million Zero-Dilution Growth Facility With New $153,000 ReachOut Customer Agreement

Customer agreement activates the new $5M financing facility for Frequency Holdings (FRQN)

Frequency announced on September 29 that ReachOut had secured $5 million in funding capacity through Capchase Pay, with eligibility to increase the facility to $10 million after 120 days.

The customer order immediately shows the purpose behind the new $5 million zero-dilution financing facility. Through Capchase Pay, ReachOut can receive payment upfront on multi-year customer agreements while customers pay Capchase over time, allowing contract cash to be brought forward and put back to work in sales, products, and continued growth.

Additional agreements are already progressing through ReachOut’s pipeline.

“We built it. Now we’re already using it,” said Rick Jordan, Founder and CEO of Frequency Holdings. “Yesterday we announced the financial infrastructure. Today we have an agreement moving through it with more to come. That is exactly what this was designed to do. Bring cash forward, put it back to work, and create a growth cycle that can keep repeating.”

From Capacity to Funding with More in the Pipeline

For ReachOut, the structure is particularly relevant to its growing model of multi-year Licensed Protection agreements, which can combine cybersecurity, software, infrastructure, equipment and ongoing technology management.

Instead of collecting the economics of those agreements incrementally over three or five years, ReachOut can accelerate the cash with participating contracts and redeploy that capital into additional growth.

“This is where the model starts to become powerful,” Jordan continued. “Sell. Fund. Deploy. Reinvest. Repeat. The first transaction matters because it takes what we announced yesterday from financial capacity to operating execution.”

Not Corporate Debt to Frequency

The Capchase structure does not represent debt issued by Frequency Holdings. Capchase provides financing to the customer purchasing products and services, while ReachOut receives payment upfront on the entire agreement. The structure gives Frequency a path to accelerate cash without issuing equity or borrowing debt at the FRQN parent-company level.

The distinction is important to Frequency’s broader capital strategy.

Earlier this month, the Company reduced its authorized common shares from 5.4 billion to 250 million and its authorized preferred shares from 1.1 billion to 250 million. Frequency has stated that its objective is to build multiple sources of growth capital rather than assuming every stage of expansion must be funded through additional equity issuance.

The nearly $153,000 transaction was entered through the newly established Capchase relationship. Frequency quickly expects additional ReachOut customer agreements to utilize the structure as the Company continues expanding its cybersecurity, Licensed Protection and managed intelligence offerings.

“We have spent a lot of time talking about structure,” Jordan said. “Now I want the conversation to increasingly be about what we do with it.”

About Frequency Holdings Inc.

Frequency Holdings is a technology-focused holding company building and acquiring assets across cybersecurity, managed intelligence, digital infrastructure, strategic technology, and media. The Company uses recurring customer relationships, proprietary products, acquisitions, and capital infrastructure to create businesses that can scale independently and become more valuable together.
Through ReachOut Digital Intelligence, Frequency provides cybersecurity-first technology, Licensed Protection, managed IT and developing managed intelligence solutions to small and midsize businesses.

Forward-Looking Statements

This press release contains forward-looking statements regarding future customer agreements, use and expansion of the Capchase facility, working capital, growth, managed intelligence commercialization and other future business activities. Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that may cause actual results to differ materially.

The Company cannot guarantee the amount or timing of future customer agreements, financing transactions, utilization or expansion of financing capacity, revenue growth or other strategic initiatives discussed herein. Frequency Holdings Inc. undertakes no obligation to publicly update or revise forward-looking statements except as required by applicable law.

Press Inquiries

Public Relations
pr [at] frequencyhold.com
3122888008
https://frequencyhold.com/

  • Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with recently disclosed evidence of persistent local immune remodeling, these findings provide mechanistic support for the long-term clinical outcomes, including disease-free survival and prolonged time to biochemical failure, time to metastasis, and time to salvage anti-cancer therapy, observed in this patient population
  • Biodistribution and shedding data from the PrTK05 phase 2 trial remain on track for inclusion in the planned Q4 2026 Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for localized prostate cancer

NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced novel immunological biomarker data from the ongoing phase 2 PrTK05 trial (NCT07332000) in patients with intermediate-risk localized prostate cancer. These data, together with histologic and clinical data from the intermediate-risk prostate cancer subgroup of the PrTK03 phase 3 trial (NCT01436968) (635 patients, 85% of the intention-to-treat population), are expected to be presented at a future scientific meeting. Intermediate-risk prostate cancer represents the largest group of patients with localized disease treated with curative-intent external beam radiation therapy (EBRT), accounting for approximately 65,000 patients annually in the United States. Despite radiotherapy, disease recurrence, local and metastatic progression, and the need for salvage anti-cancer therapies that can be associated with substantial toxicity and impaired quality of life remain important unmet needs. This underscores the need for new treatments designed to enhance local tumor control and reduce the risk of disease progression.

PrTK03 Clinical Outcomes

With follow-up through March 15, 2026 (median, 58.0 months), the phase 3 trial showed that patients with intermediate-risk disease (635 patients) treated with aglatimagene plus EBRT experienced a 41% reduction in the risk of prostate cancer recurrence or prostate cancer-specific death versus placebo plus EBRT (HR 0.59; 95% CI 0.41–0.84; p=0.0034).

Additional exploratory, descriptive analyses showed 52% improvement in the time to biochemical failure (HR 0.48; 95% CI 0.22–1.03), a 90% improvement in the time to metastasis (HR=0.10; 95% CI 0.01–0.85), and a 49% reduction in the time to salvage anticancer therapy (HR 0.51; 95% CI 0.24–1.10).

PrTK03 Pathologic and Biomarker Data

Centrally reviewed biopsies from patients with intermediate-risk disease obtained 22–26 months after treatment demonstrated a substantial improvement in rate of negative biopsies, defined as the absence of tumor cells in a standard-of-care diagnostic prostate biopsy. Among 277 evaluable patients with intermediate-risk disease:

  • 76.6% (144/188) in the aglatimagene arm had negative biopsies versus 60.7% (54/89) in the control arm
  • Positive biopsies were observed in 20.7% of the aglatimagene arm and 38.2% of the control arm (stratified CMH p = 0.0034; chi-square p = 0.0026). Six undetermined biopsies were included in the total number of biopsies analyzed and are part of the denominator.

Building on the AI-enabled histologic analysis presented at ASTRO, exploratory digital pathology analyses showed:

  • Increased lymphocytic infiltration after treatment in both arms (p<0.001)
  • In paired biopsies with detectable post-treatment tumor (n=98), aglatimagene increased the intratumoral lymphocyte fraction (p=0.002) and lymphocyte–tumor enrichment and mixing scores (both p<0.001)

These immune changes were observed more than two years after treatment.

PrTK05 Systemic Immune Response Data

Early data from the PrTK05 flow-cytometry analyses provided evidence that local treatment with aglatimagene is associated with systemic expansion and activation of multiple circulating cytotoxic T-cell populations. Serial blood samples from 13 patients with intermediate-risk prostate cancer, treated with aglatimagene plus standard-of-care (SoC) EBRT, and 6 patients receiving SoC alone showed expansion of CD8-positive effector and effector-memory T cell populations in the aglatimagene arm, alongside expansion of Ki67-positive proliferating and granzyme B-positive cytotoxic CD8-positive T-cells. These longitudinal findings extend the local PrTK03 tissue observations by suggesting a coordinated systemic immune response beyond the locally treated prostate; formal comparison with SoC-treated controls is ongoing.

Together, these analyses provide complementary evidence of durable local tumor clearance and immune remodeling within the prostate, along with systemic expansion and activation of cytotoxic T-cell populations beyond the treated tumor.

“This signature of coordinated immune activation across tissue and blood in prostate cancer is consistent with findings previously observed following aglatimagene treatment in other solid tumor indications, including NSCLC and high-grade glioma,” said Francesca Barone, M.D., Ph.D., Chief Scientific Officer of Candel Therapeutics. “These findings are consistent with a shared mechanism across solid tumors involving immunogenic tumor cell death followed by individualized local and systemic anti-tumor immunity that does not depend on a predefined antigen or biomarker.”

Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel Therapeutics, added, “The evidence of systemic immune activation in intermediate-risk prostate cancer strengthens the biological rationale for evaluating aglatimagene in metastatic solid tumor settings where systemic disease control is critical. These findings underscore the broader potential of our multimodal immunotherapy platform.”

The biodistribution and shedding data from the phase 2 PrTK05 trial have been compiled for inclusion in Candel’s BLA for aglatimagene in localized prostate cancer, which the Company plans to submit to the FDA in Q4 2026. The Company intends to submit the data for presentation at an upcoming scientific conference and for potential publication in a peer-reviewed journal in 2027.        

About aglatimagene besadenovec

Aglatimagene besadenovec (aglatimagene), Candel’s most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s tumor. After intratumoral administration, HSV-tk enzyme activity results in conversion of prodrug (valacyclovir) into deoxyribonucleic acid (DNA)-incorporating nucleotide analogs, leading to immunogenic cell death in cells exhibiting DNA damage and proliferating cells, with subsequent release of a variety of tumor (neo)antigens in the tumor microenvironment. At the same time, the adenoviral serotype 5 capsid proteins promote inflammation through the induction of expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. Together, this regimen is designed to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity, based on in situ immunization against a variety of tumor antigens. Aglatimagene has the potential to treat a broad range of solid tumors. Encouraging monotherapy activity as well as combination activity with standard of care radiotherapy, surgery, chemotherapy, and immune checkpoint inhibitors have previously been shown in several nonclinical and clinical settings. More than 1,000 patients have been dosed with aglatimagene in clinical trials with a favorable tolerability profile to date, supporting the potential for use with standard of care, when indicated. Aglatimagene is currently not approved by the FDA or any other regulatory authority for any use.

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (aglatimagene) is the lead product candidate from the adenovirus platform. The Company completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the FDA and published in The Lancet Oncology. The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.

Linoserpaturev is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit: www.candeltx.com.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs, including expectations regarding planned BLA submission and potential commercial readiness; expectations regarding the therapeutic benefit of the Company’s platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult-to-treat, solid tumors; and expectations regarding the potential benefits conferred by regulatory designations. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s nonclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; the impact of the Company’s existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Investor Contact
Theodore Jenkins
Vice President, Investor Relations, and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com

Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com

Following Its First Acquisition as a Public Company, Autoentrada in Argentina, Ticketplus Outlines Its Growth Priorities

As CEO of NYSE-Listed CorpBanca, Mr. Massú Led the Approximately US$1.3 Billion Acquisition of Helm Bank in Colombia and Played a Leading Role in the Merger with Itaú

SANTIAGO, Chile, Sept. 30, 2026 (GLOBE NEWSWIRE) — Ticketplus Ltd. (“Ticketplus” or the “Company”) (NYSE American: TP), a technology company that operates a proprietary, full-stack platform for the live-entertainment industry in Latin America, today announced the engagement of Fernando Massú Taré, Chairman of Banco BTG Pactual Chile and former Chief Executive Officer of CorpBanca, as the Company’s Lead Strategic Advisor, LATAM Regional Strategy and Governance, and his role in the next phase of the Company’s regional expansion plan. Mr. Massú serves as a strategic advisor in his individual capacity and will work with the Company’s Chairman, Yethro Dinamarca, the Chief Executive Officer, Chien-Fu Chen, and the Board of Directors on the Company’s expansion roadmap, including market entry priorities, potential acquisitions and strategic partnerships, capital allocation and corporate governance.

The acquisition of Autoentrada S.A. converted a seven-year white-label partner into a wholly owned, full-service operation and brought the Ticketplus brand to Argentina. For additional details regarding the Autoentrada acquisition, see the Company’s report on Form 6-K filed with the SEC on September 22, 2026. The Company believes this is an important step in executing its growth strategy: deepening its presence across the 11 countries where it currently operates, expanding into new white-label markets, and pursuing strategic partnerships to extend the reach of its platform.

“We recently announced our first acquisition as a public company, bringing the Ticketplus brand to Argentina and expanding our direct operating footprint. This acquisition is part of a broader strategy to deepen our presence in existing markets, enter new markets and scale our platform through partnerships and selective acquisitions,” said Yethro Dinamarca, Chairman of the Board of Ticketplus. “We believe a plan of this magnitude requires people who have done it before. Fernando brings a proven track record in cross-border expansion in financial services across Latin America. He knows what it takes to grow across countries with discipline and strong governance. He will work closely with Chien, our Board and me to build a roadmap for where we expand next and in what order. We also anticipate growing the team to support these efforts. We expect to execute our plan market by market and to give investors a clear way to measure our progress.”

A track record of cross-border expansion in Latin America

Mr. Massú has more than four decades of experience in Latin American financial services, including senior leadership roles spanning banking, investment banking and capital markets. He began his career at Citibank in Chile and spent more than 15 years at Banco Santander, where his roles included Chief Financial Officer of its banking operation in Portugal and head of Wholesale Banking in Chile.

As CEO of CorpBanca from 2012 to 2016, he completed the acquisition of Banco Santander Colombia in 2012 and led the acquisition of Helm Bank, with operations in Colombia and Panama, in 2013, an investment of approximately US$1.3 billion. Through those transactions, CorpBanca became the first Chilean bank to acquire a universal bank in Colombia, and as of December 31, 2015, CorpBanca Colombia was the country’s sixth-largest bank by total assets. He subsequently played a leading role in CorpBanca’s merger with Itaú Chile, which created the fourth-largest private bank in Chile.

During his tenure, CorpBanca was a foreign private issuer with American Depositary Shares listed on the New York Stock Exchange under the ticker BCA, giving Mr. Massú direct experience leading a company subject to SEC reporting and NYSE listing requirements.

Since 2016, he has served as Chairman of Banco BTG Pactual Chile. He is also a director of Parque Arauco, a shopping center operator with assets in Chile, Peru and Colombia, and of Empresas Hites. He previously served as Chairman of ENAP, Chile’s national oil company, and as an independent director of SQM, the NYSE-listed lithium producer. He holds a business degree from Universidad Adolfo Ibáñez and completed the Program for Management Development at Harvard Business School.

Growth priorities

Ticketplus’s growth plan centers on four priorities: transitioning proven white-label partnerships into wholly owned, full-service operations; entering new markets through its white-label SaaS model; continuing to enhance its payments, access control, data and analytics capabilities; and building strategic partnerships with content owners, promoters, venues and other related companies. The Company intends to pursue acquisitions selectively to support these priorities. Ticketplus intends to track progress through metrics that may include Total Platform Sales (GMV), events processed and active markets, among other measures.

About Ticketplus

Ticketplus Ltd. (NYSE American: TP) is a technology company that operates a proprietary, full-stack platform for the live-entertainment industry in Latin America, integrating ticketing, payments, access control and analytics. The Company operates through a full-operations model and a white-label SaaS model across 11 countries: Argentina, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Mexico, Paraguay, Peru, the United States, and Uruguay. In 2025, the Ticketplus platform processed more than 10.2 million tickets across more than 39,800 events. For more information, please visit the Ticketplus investor relations website at investors.ticketplus.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements about the Company’s growth strategy, expansion into new markets, potential acquisitions, conversions and partnerships, the expected contribution of Mr. Massú, and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “goal,” “objective,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These forward-looking statements are not guarantees of future performance and are subject to risks that could cause material differences, including market conditions, developments in live entertainment, promoter and client relationships, competition, regulatory conditions in the markets in which we operate or may enter, integration and other risks described in the Company’s SEC filings. Readers should not place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update any forward-looking statements except as may be required by law.

Investor Contact

Jack Perkins
KCSA Strategic Communications
Ticketplus@kcsa.com

FREDERICK, Md., Sept. 30, 2026 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today announced Project MEND, a San Antonio-based nonprofit that refurbishes and redistributes used medical equipment to people with disabilities and limited financial resources, has implemented SteraMist iHP. The system has helped Project MEND’s team disinfect reusable durable medical equipment (DME), including wheelchairs, walkers, hospital beds and mobility aids, before it is returned to service for a new recipient.

Every piece of equipment that comes through Project MEND has a previous owner, and many recipients are older adults, children or individuals with compromised health who depend on that equipment being fully clean before it enters their home. SteraMist meets that need by reaching the frames, wheels, upholstery and hard-to-access joints of mobility equipment without damaging vinyl, foam, electronics or metal components, a fit well suited to the wide range of equipment Project MEND handles daily.

“Every wheelchair, walker and hospital bed we redistribute has to meet the same standard of safety as new equipment. SteraMist iHP gives our team a faster, more thorough way to disinfect equipment before it reaches the families who need it,” said Dexter Moon, COO at Project MEND.

Project MEND introduced SteraMist to community members at the Houston Ability Expo earlier this year, where SteraMist disinfection was demonstrated alongside Project MEND’s inventory of refurbished wheelchairs and mobility devices.

“Project MEND has been an exceptional partner,” said Brittany Buchman, Vice President of Marketing at TOMI Environmental Solutions. “They’ve showcased SteraMist at multiple conferences this year, helping build awareness across their community. We are continuing that work together through additional initiatives, because every durable medical equipment (DME) provider should know how SteraMist can help them safeguard the people they serve.”

Founded in 1992 and incorporated as a 501(c)(3) nonprofit in 1993, Project MEND, short for Medical Equipment Network for those with Disabilities, has spent more than three decades refurbishing and redistributing donated medical equipment across the San Antonio community. In 2024 alone, the organization served 2,683 clients and distributed 6,244 pieces of equipment, including wheelchairs, power chairs, walkers, hospital beds, Hoyer lifts, scooters, shower chairs, rollators, commodes, trapezes and tub transfer benches, while keeping an estimated 74 tons of scrap metal out of area landfills.

The same SteraMist iHP science used to disinfect operating rooms, cleanrooms and ambulances is now helping ensure that a second-hand wheelchair or hospital bed can be trusted as being as safe as the day it first left the factory.

About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®

TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company providing environmental disinfection and bio-decontamination solutions through manufacturing, sales, and licensing of its Binary Ionization Technology® (BIT®) platform. Developed under a defense grant with DARPA, BIT® utilizes low-percentage hydrogen peroxide to produce ionized hydrogen peroxide (iHP®) fog. SteraMist® products serve hospitals, laboratories, government and military installations, cruise ships, office buildings, schools, restaurants, food processing facilities, and residences, delivering protection against a broad range of bacteria, viruses, mold, mycotoxins, and biological and chemical warfare agents. For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services to serve the commercial and healthcare sector. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.

INVESTOR RELATIONS CONTACT: 
John Nesbett/Zach Nevas
IMS Investor Relations 
tomi@imsinvestorrelations.com  

IRVINE, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — Skyworks Solutions, Inc. (Nasdaq: SWKS) today announced that it has received all necessary regulatory clearances to proceed with the previously announced transaction with Qorvo, Inc. (Nasdaq: QRVO) (the “Mergers”). The parties expect to close the Mergers on or about October 5, 2026, subject to the satisfaction or waiver of the remaining customary closing conditions.

Skyworks and Qorvo previously announced on October 28, 2025 their agreement to combine in a cash-and-stock transaction, bringing together the companies’ complementary product and technology portfolios and world-class engineering capabilities. The combination will create a U.S.-based, global leader in high-performance radio frequency, analog and mixed-signal semiconductors.

In connection with the transaction, Skyworks previously announced offers to exchange any and all of the outstanding 4.375% Senior Notes due 2029 issued by Qorvo and any and all of the outstanding 3.375% Senior Notes due 2031 issued by Qorvo, in each case for new notes issued by Skyworks (together with related consent solicitations for proposed amendments to the applicable indenture governing each series of such Qorvo notes), pursuant to the terms and subject to the conditions set forth in Skyworks’ registration statement on Form S-4, which was declared effective on May 29, 2026, and the related final prospectus filed with the Securities and Exchange Commission (the “SEC”) on May 29, 2026 (as it may be amended or supplemented from time to time, the “Prospectus”). Each exchange offer and consent solicitation is conditioned upon the closing of the Mergers, which condition may not be waived by Skyworks. The closing of the Mergers is not conditioned upon the results of the exchange offers and consent solicitations.

Skyworks expects to pay the Consent Payments (as defined in the Prospectus) with respect to the consent solicitations concurrently with, or promptly following, the closing of the Mergers. The related exchange offers currently are expected to expire at 5:00 p.m., New York City time, on October 2, 2026. Skyworks anticipates issuing a separate press release to extend the expiration date of the exchange offers to a date and time following the closing of the Mergers.

About Skyworks

Skyworks Solutions, Inc. is empowering the wireless networking revolution. We are a leading developer, manufacturer and provider of analog and mixed-signal semiconductors and solutions for numerous applications, including aerospace, automotive, broadband, cellular infrastructure, connected home, defense, entertainment and gaming, industrial, medical, smartphone, tablet and wearables.

Skyworks is a global company with engineering, marketing, operations, sales and support facilities located throughout Asia, Europe and North America and is a member of the S&P 500® market index (Nasdaq: SWKS). For more information, please visit Skyworks’ website at: www.skyworksinc.com.

Important Information About the Proposed Transaction and Where to Find It

In connection with the proposed Mergers with Qorvo, Skyworks has filed with the SEC a registration statement on Form S-4 (File No. 333-291947) (the “Registration Statement”), which includes a prospectus with respect to the shares of Skyworks’ common stock to be issued in the Mergers and a joint proxy statement for Skyworks’ and Qorvo’s respective stockholders (the “Joint Proxy Statement/Prospectus”). The Registration Statement was declared effective on December 23, 2025, and Skyworks filed a final prospectus on December 23, 2025, and Qorvo filed a definitive proxy statement on December 23, 2025. The Joint Proxy Statement/Prospectus was mailed to stockholders of Skyworks and Qorvo on or about December 23, 2025. Each of Skyworks and Qorvo may also file with or furnish to the SEC other relevant documents regarding the Mergers. This communication is not a substitute for the Registration Statement, the Joint Proxy Statement/Prospectus or any other document that Skyworks or Qorvo may mail to their respective stockholders in connection with the Mergers.

INVESTORS AND SECURITY HOLDERS OF SKYWORKS AND QORVO ARE URGED TO READ THE REGISTRATION STATEMENT AND THE JOINT PROXY STATEMENT/PROSPECTUS INCLUDED WITHIN THE REGISTRATION STATEMENT, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE MERGERS OR INCORPORATED BY REFERENCE INTO THE REGISTRATION STATEMENT AND THE JOINT PROXY STATEMENT/PROSPECTUS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION REGARDING SKYWORKS, QORVO, THE MERGERS AND RELATED MATTERS.

The documents filed by Skyworks with the SEC also may be obtained free of charge at Skyworks’ website at https://www.skyworksinc.com/investors or upon written request to Skyworks at investor.relations@skyworksinc.com. The documents filed by Qorvo with the SEC also may be obtained free of charge at Qorvo’s website at https://ir.qorvo.com/ or upon written request to Qorvo at investor-relations@qorvo.com. These documents filed with the SEC are also available for free to the public at the website maintained by the SEC at www.sec.gov.

No Offer or Solicitation

This communication is for informational purposes only and does not constitute, or form a part of, an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any tender, consent, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities Act”), and otherwise in accordance with applicable law.

The exchange offers and consent solicitations are being made solely pursuant to the Prospectus and only to such persons and in such jurisdictions as is permitted under applicable law.

Cautionary Statement Regarding Forward-Looking Statements

This document contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on Skyworks’ and Qorvo’s current expectations, estimates and projections about the expected date of closing of the Mergers, the exchange offers and the consent solicitations and the potential benefits thereof, their respective businesses and industries, management’s beliefs and certain assumptions made by Skyworks and Qorvo, all of which are subject to change. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “could,” “seek,” “see,” “will,” “may,” “would,” “might,” “potentially,” “estimate,” “continue,” “expect,” “target,” similar expressions or the negatives of these words or other comparable terminology that convey uncertainty of future events or outcomes. All forward-looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond our control and are not guarantees of future results, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. These and other forward-looking statements, including the failure to consummate the proposed transaction or to make or take any filing or other action required to consummate the transaction in a timely matter or at all, are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements and caution must be exercised in relying on forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to: (i) the completion of the proposed transaction on anticipated terms and timing, including anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies, expansion and growth of Skyworks’ and Qorvo’s businesses and other conditions to the completion of the proposed transaction; (ii) failure to realize the anticipated benefits of the proposed transaction, including as a result of delay in completing the transaction or integrating the businesses of Skyworks and Qorvo; (iii) Skyworks’ and Qorvo’s ability to implement their business strategies; (iv) pricing trends; (v) potential litigation relating to the proposed transaction that has been or could be instituted against Skyworks, Qorvo or their respective directors; (vi) the risk that disruptions from the proposed transaction will harm Skyworks’ or Qorvo’s business, including current plans and operations; (vii) the ability of Skyworks or Qorvo to retain and hire key personnel; (viii) potential adverse reactions or changes to business relationships resulting from the announcement, pendency or completion of the proposed transaction; (ix) uncertainty as to the long-term value of Skyworks’ common stock; (x) legislative, regulatory and economic developments affecting Skyworks’ and Qorvo’s businesses; (xi) general economic and market developments and conditions; (xii) the evolving legal, regulatory and tax regimes under which Skyworks and Qorvo operate; (xiii) potential business uncertainty, including changes to existing business relationships, during the pendency of the proposed transaction that could affect Skyworks’ or Qorvo’s financial performance; (xiv) restrictions during the pendency of the proposed transaction that may impact Skyworks’ or Qorvo’s ability to pursue certain business opportunities or strategic transactions; and (xv) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as Skyworks’ and Qorvo’s response to any of the aforementioned factors. These risks, as well as other risks associated with the proposed transaction, are more fully discussed in the Joint Proxy Statement/Prospectus. While the list of factors presented here and in the Joint Proxy Statement/Prospectus are considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Skyworks’ or Qorvo’s consolidated financial condition, results of operations or liquidity. Neither Skyworks nor Qorvo assumes any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

CONTACT: Skyworks Contacts:

Media Contact:
Constance Griffiths
(949) 230-4867
Constance.Griffiths@skyworksinc.com

Investor Relations:
Raji Gill
(949) 508-0973
Raji.Gill@skyworksinc.com

BRAMPTON, Ontario, Sept. 30, 2026 (GLOBE NEWSWIRE) — Loblaw Companies Limited applauds the Competition Bureau’s decision to investigate the use of minimum advertised pricing policies. These policies are employed by some of the world’s largest global consumer packaged goods (CPG) companies and can serve to constrain retailers from advertising lower grocery prices, ultimately impacting grocery costs for Canadians.

We also support the Competition Bureau’s comprehensive review of competition across the entire food supply chain which is critical to better understand all major factors driving the cost of food for Canadians. 

At Loblaw, we know affordability remains a key concern for many customers. Between promotions, PC Optimum offers, our strong control brands and our investments in discount banners, we are committed to ​working to help Canadians manage their household budgets and do our part to reduce pressure on grocery costs.

About Loblaw Companies Limited

Loblaw Companies Limited is a Canadian public company incorporated in 1956 and is Canada’s food and pharmacy leader, and the nation’s largest retailer. The Company’s continuing retail operations are comprised of several operating segments and now represent the only reportable segment due to the similar nature of the products and services offered. All material operations are carried out in Canada. The segment consists primarily of corporate and franchise-owned retail food and Associate-owned drug stores and e-commerce platforms, and includes in-store pharmacies, healthcare services, other health and beauty products, apparel, other general merchandise, wireless products and services, logistics services, retail media and the PC OptimumTM loyalty program. The Company also provided credit card and everyday banking services and insurance brokerage services through its PC Financial business, until its sale to EQB Inc. on July 1, 2026. PC Financial’s results, net of intersegment eliminations, have been presented separately as discontinued operations in the Company’s current and comparative results.

For more information, contact pr@loblaw.ca.

Houston, Texas, Sept. 30, 2026 (GLOBE NEWSWIRE) — Battalion Oil Corporation (NYSE American: BATL) (“Battalion” or the “Company”) today announced the release of its updated September 2026 investor presentation, outlining the Company’s strategic priorities, operational progress, financial position and outlook. The presentation is available in the Investor Events and Presentations section of the Company’s website at www.battalionoil.com.

The presentation covers the following topics:

  • Strategic priorities and the Company’s transformation
  • Delaware Basin asset portfolio, operational enhancements and development activity
  • Balance-sheet transformation, capital structure, liquidity and funding strategy
  • 2026 and 2027 guidance, capital-efficient growth and strategic value-creation opportunities

The Company remains committed to providing investors with regular, transparent updates on its operating performance, financial position and strategic priorities.

Management Comments

“Over the past year, Battalion has taken significant steps to strengthen its balance sheet, high-grade its Delaware Basin acreage position and establish a capital-efficient operating platform for growth,” said Matthew B. Steele, Chief Executive Officer. “This presentation gives investors a comprehensive update on our progress, current operating and financial position, and strategic priorities to create long-term shareholder value.”

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements that are not strictly historical statements constitute forward-looking statements. Forward-looking statements in this release and in the investor presentation include, among others, statements about the Company’s strategy, anticipated production, liquidity, capital structure, capital spending, drilling and completion plans, guidance, the Company’s Joint Exploration and Development Agreement, potential acquisitions, preferred stock retirement, potential data center and power generation development, use of the Company’s at-the-market equity program, and outlook. Forward-looking statements may often, but not always, be identified by the use of words such as “expects,” “believes,” “intends,” “anticipates,” “plans,” “estimates,” “projects,” “potential,” “possible” or “probable,” or statements that certain actions, events or results “may,” “will,” “should” or “could” be taken, occur or be achieved. Forward-looking statements are based on current beliefs and expectations, involve certain assumptions or estimates, and are subject to risks and uncertainties that could cause actual results to differ materially from those reflected in the statements. These risks include, but are not limited to, those set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, its subsequent Quarterly Reports on Form 10-Q, its Current Reports on Form 8-K, and other filings made by the Company with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained from the SEC’s website at www.sec.gov or through the Company’s website at www.battalionoil.com. Readers should not place undue reliance on any such forward-looking statements, which are made only as of the date hereof. Except as required by applicable law, the Company has no duty, and assumes no obligation, to update forward-looking statements as a result of new information, future events or changes in the Company’s expectations.

About Battalion

Battalion Oil Corporation is an independent energy company engaged in the acquisition, production, exploration and development of onshore oil and natural gas properties in the United States.

CONTACT: BATTALION OIL CORPORATION
Matthew B. Steele
Chief Executive Officer
832-538-0300 | www.battalionoil.com

CEO Rick Pierce to deliver an investor presentation on Thursday, October 1 in New York

CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) — Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across many viruses, today announced that Rick Pierce, Chief Executive Officer, will present at The Small Cap Showcase, taking place Thursday, October 1, 2026 in New York City.

Mr. Pierce will deliver a corporate overview and participate in one-on-one meetings with investors during the conference.

Details of the presentation are as follows:

Date: Thursday, October 1, 2026
Time: 11:30 a.m. ET
Location: New York, NY
Presenter: Rick Pierce, Chief Executive Officer of Decoy Therapeutics
Webcast: https://www.webcaster5.com/Webcast/Page/3173/54586
More information: https://www.smallcapshowcase.com

Decoy designs peptide antivirals intended to work across many viruses rather than one drug for one virus. The Company’s IMP³ACT™ platform pairs AI-enabled design with rapid synthesis and testing, and its lead program targets many respiratory viruses as it advances toward the clinic.

About The Small Cap Showcase

The Small Cap Showcase is a curated, single-day investor conference in New York City that brings together a limited group of roughly ten public small cap companies with institutional investors, family offices and professional investors. Kept intentionally small, the program includes company presentations, one-on-one meetings, fireside chats and networking, with an emphasis on building lasting relationships between companies and investors.

About Decoy Therapeutics, Inc.
Decoy Therapeutics (NASDAQ: DCOY) is a biotechnology company developing Designable Multi-Antivirals (D-MAVs™) powered by its proprietary IMP³ACT™ platform. By combining generative AI structural design with advanced peptide-conjugate chemistry, Decoy creates single therapeutics that target conserved viral entry machinery across entire viral families. Decoy’s pipeline includes programs targeting endemic coronaviruses (COVID-19, MERS), paramyxoviruses (RSV, hPIV, Nipah, Measles), and filoviruses (Ebola, Marburg). For more information, visit decoytx.com.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Decoy, including expected achievement of milestones for its lead asset and future prospects of Decoy. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Decoy, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “can,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the Company will not obtain sufficient financing to execute on their business plans and risks related to Decoy’s products and development plans, including unanticipated issues with any IND application process and the potential of the IMP³ACT™ platform. Readers are urged to carefully review and consider the various disclosures made by the Company in its reports filed with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Decoy’s actual results may vary materially from those expected or projected.

Business Development Contact:
Peter Marschel, Chief Business Officer
Email: peter@decoytx.com | Phone: 617-943-6305

Media Relations Contact:
Tara Mulloy, TMC Studio
Email: tara@tmc-studio.com | Phone: 978-855-5219

Hong Kong, Sept. 30, 2026 (GLOBE NEWSWIRE) — Rich Sparkle Holdings Limited (“we”, “ANPA” or the “Company”) (Nasdaq: ANPA) is a company with limited liability incorporated under the laws of the British Virgin Islands (“BVI”) with no material operations of its own. The Company conduct its operations as a professional specialist in the provision of financial printing services such as printing, typesetting and translation, advisory services including Environmental, Social and Governance (“ESG”) and internal control reporting services and other services including standalone annual general meeting and extraordinary general meeting supporting service and other standalone services, through ANPA Financial Services Group Limited (“ANPA (HK)”), its sole operating subsidiary in Hong Kong.

The Company today announced its unaudited financial results for the six months ended March 31, 2026.

First Half of 2025/26 Financial and Operating Highlights

  ● Total revenue increased] by 21.8% from US$1,741,985 to US$2,121,062
     
  ● Gross profit increased by 32.2% from US$632,059 to US$835,774
     
  ● Net loss and total comprehensive loss increased by 15,093.8% from US$259,984 to US$39,501,480

FINANCIAL RESULTS

Revenue

Revenue increased by US$379,077 or 21.8% to US$2,121,062 for the six months ended March 31, 2026 from US$1,741,985 for the six months ended March 31, 2025. Such increase was mainly attributable to the increase of financial printing services of US$834,492 and the increase of advisory services of US$167,998, which was partially offset by the decrease of other services of US$623,413.

For the six months ended March 31, 2026 and 2025, all of the revenue was from clients in Hong Kong.

Cost of services

During the six months ended March 31, 2026 and 2025, our Group’s cost of services was mainly comprised of staff costs, subcontracting fee, printing costs and other job-specific expenses. We incurred cost of services of US$1,285,288 for the six months ended March 31, 2026, compared to US$1,109,926 for the six months ended March 31, 2025, an increase of US$175,362 or 15.8%. The increase was in line with the increase in revenue from financial printing services. The increase in subcontracting fee was resulted from the reduced reliance on the internal resources.

The Company paid subcontracting fee for (i) translation services handled by professional linguists who ensure accuracy and cultural relevance, (ii) ESG and internal control services support, and (iii) client relationship maintenance support.

Gross profit and gross profit margin

The total gross profit was US$835,774 for the six months ended March 31, 2026, compared to US$632,059 for the six months ended March 31, 2025, an increase of US$203,715, or 32.2%. Our overall gross profit margins were 39.4% and 36.3% for the six months ended March 31, 2026 and 2025, respectively. Our total gross profit increased during the six months ended March 31, 2026, due to the increase in revenue from the financial printing services and advisory services which are generally with higher gross profit margins.

Selling, General and Administrative expenses

Selling, general and administrative expenses (“SG&A”) mainly consist of administrative staff cost, depreciation of property, plant and equipment and right-of-use assets, property related expenses, legal and professional fees and other miscellaneous expenses. Our SG&A were US$1,555,814 and US$905,329 for the six months ended March 31, 2026 and 2025, respectively, or 73.4% and 52.0% of our revenue for the corresponding period. The increase was mainly due to the increase in our staff costs, depreciation, legal and professional fees and advertising and marketing expenses.

Share-based compensation expense

Our share-based compensation expense was US$38,850,000 for the six months ended March 31, 2026, compared to nil for the six months ended March 31, 2025, an increase of US$38,850,000. Share-based compensation expense increased during the six months ended March 31, 2026, due to the issuance of 2,500,000 ordinary shares to the staff of the Company pursuant to the equity incentive plan.

Other Expense, Net

The other expense were expense of US$14,358 and of US$31,682 for the six months ended March 31, 2026 and 2025, respectively.

An decrease in other expense by US$17,324 or 54.7%, for the six months ended March 31, 2026, compared to the corresponding six months ended March 31, 2025, was primarily attributable to the decrease of interest expense on lease liabilities of US$14,303.

Income Tax Expenses

The Company and our wholly owned subsidiary, Lore, were incorporated in the BVI. Pursuant to the current rules and regulations, the BVI currently levy no taxes on individuals or corporations based upon profits, income, gains or appreciations and there is no taxation in the nature of inheritance tax or estate duty. Therefore, the Company is not subject to any income tax in the BVI.

The indirectly wholly-owned subsidiary, ANPA (HK), is subject to income tax within Hong Kong at the applicable tax rate on taxable income. Hong Kong profit tax rates are 8.25% on assessable profits up to HK$2,000,000 (US$255,135), and 16.5% on any part of assessable profits over HK$2,000,000 (US$255,135). For the six months ended March 31, 2026 and 2025, our Group did not have any assessable profits in Hong Kong.

The Company had income tax benefit of US$121,176 for the six months ended March 31, 2026, compared to US$48,167 for the six months ended March 31, 2025, an increase of US$73,009, or 151.6%, mainly due to the increase in loss before taxation. Our effective tax rate was 16.5% for the six months ended March 31, 2026 and 16.5% for the six months ended March 31, 2025.

 Net loss

As a result of the foregoing, our net loss for the six months ended March 31, 2026 and 2025 was US$39,463,222 and US$256,785, respectively.

About Rich Sparkle Holdings Limited

Founded in 2016, the Company is a financial printing and corporate services provider which specializes in designing and printing high quality financial print materials in Hong Kong. The Company’s service portfolio covers a myriad of deliverables, mainly including listing documents, financial reports, fund documents, circulars and announcements. The Company offers to its customers a wide range of convenient and quality financial printing services, from typesetting, proofreading, translation, design and printing. In addition, the Company also offered advisory services which could cater for its customers’ different requirements, such as conducting internal control assessment and environmental, social and governance (“ESG”) performance evaluation as well as other services including provision of co-working space at its leased office located at Portion 2, 12th Floor, The Center, 99 Queen’s Road Central, Hong Kong, for its customers mainly to conduct meetings and conferences.

For more information, please visit the Company’s website: http://www.anpa.com.hk/.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may,” or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s announcement and other filings with the SEC.

For more information, please contact:

Rich Sparkle Holdings Limited
Email: anpa.info@anpa.com.hk

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.